FOSFODIESTERASAS DEL AMPc Y DEL GMPc EN EL
CEREBRO: EXPRESIÓN EN PROCESOS
NEUROINFLAMATORIOS Y NEURODEGENERATIVOS
171
Bibliografía
173
't Hart BA, Amor S, and Jonker M. 2004. Evaluating the validity of animal models for research into therapies for immune-based disorders. Drug Discovery Today 9:517-524. Abbott NJ and Romero IA. 1996. Transporting
therapeutics across the blood-brain barrier. Mol Med Today 2:106-113.
Abdel-Latif AA. 2001. Cross talk between cyclic nucleotides and polyphosphoinositide hydrolysis, protein kinases, and contraction in smooth muscle. Exp Biol Med 226:153-163. Abrahamsen H, Baillie G, Ngai J, Vang T, Nika K,
Ruppelt A, Mustelin T, Zaccolo M, Houslay M, and Tasken K. 2004. TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J Immunol 173:4847-4858.
Adachi H, Kakiki M, and Kishi Y. 2005. Effects of a phosphodiesterase 3 inhibitor, olprinone, on rhythmical change in tension of human gastroepiploic artery. Eur J Pharmacol 528:137-143.
Ahmed T and Frey JU. 2003. Expression of the specific type IV phosphodiesterase gene PDE4B3 during different phases of long-term potentiation in single hippocampal slices of rats in vitro. Neuroscience 117:627-638. Airaksinen E, Larsson M, Lundberg I, and Forsell
Y. 2004. Cognitive functions in depressive disorders: evidence from a population-based study. Psychol Med 34:83-91.
Aisen PS, Marin D, Altstiel L, Goodwin C, Baruch B, Jacobson R, Ryan T, and Davis KL. 1996. A pilot study of prednisone in Alzheimer's disease. Dementia 7:201-206.
Akasaka S, Nomura M, Nishii H, Fujimoto N, Ueta Y, Tsutsui M, Shimokawa H, Yanagihara N, and Matsumoto T. 2006. The hypothalamo-pituitary axis responses to lipopolysaccharide-induced endotoxemia in mice lacking inducible nitric oxide synthase. Brain Res 1089:1-9. Akwa Y, Hassett DE, Eloranta ML, Sandberg K,
Masliah E, Powell H, Whitton JL, Bloom FE, and Campbell IL. 1998. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol 161:5016-5026.
Albert PR, Sajedi N, Lemonde S, and Ghahremani MH. 1999. Constitutive G(i2)-dependent activation of adenylyl cyclase type II by the 5-HT1A receptor. Inhibition by anxiolytic partial agonists. J Biol Chem 274:35469-35474. Alexander SPH, Mathie A, and Peters JA. 2004.
Guide to receptors and channels, 1st edition. British Journal of Pharmacology 141:S1-S126. Altmann DM and Boyton RJ. 2004. Models of
multiple sclerosis. Drug Discovery Today 1:405-410.
Alvarez R, Sette C, Yang D, Eglen RM, Wilhelm R, Shelton ER, and Conti M. 1995. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol Pharmacol 48:616-622.
Andersson PB, Perry VH, and Gordon S. 1992. The acute inflammatory response to lipopolysaccharide in CNS parenchyma differs from that in other body tissues. Neuroscience 48:169-186.
Andjelkovic AV, Nikolic B, Pachter JS, and Zecevic N. 1998. Macrophages/microglial cells in human central nervous system during development: an immunohistochemical study. Brain Res 814:13-25.
Andoh T, Chock PB, and Chiueh CC. 2002. Preconditioning-mediated neuroprotection: role of nitric oxide, cGMP, and new protein expression. Ann N Y Acad Sci 962:1-7.
Andreeva SG, Dikkes P, Epstein PM, and Rosenberg PA. 2001. Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain. J Neurosci 21:9068-9076.
Angelov DN, Walther M, Streppel M, Guntinas-Lichius O, and Neiss WF. 1998. The cerebral perivascular cells. Adv Anat Embryol Cell Biol 147:1-87.
Archelos JJ, Jung S, Maurer M, Schmied M, Lassmann H, Tamatani T, Miyasaka M, Toyka KV, and Hartung HP. 1993. Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Ann Neurol 34:145-154. Ariga M, Neitzert B, Nakae S, Mottin G, Bertrand
C, Pruniaux MP, Jin SL, and Conti M. 2004. Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J Immunol 173:7531-7538. Arp J, Kirchhof MG, Baroja ML, Nazarian SH,
Chau TA, Strathdee CA, Ball EH, and Madrenas J. 2003. Regulation of T-cell activation by phosphodiesterase 4B2 requires its dynamic redistribution during immunological synapse formation. Mol Cell Biol 23:8042-8057.
ASHMAN DF, PRICE TD, MELICOW MM, and LIPTON R. 1963. Isolation of Adenosine Monophosphate and Guanosine 3,5-Monophosphate from Rat Urine. Biochemical and Biophysical Research Communications 11:330-&.
Asirvatham AL, Galligan SG, Schillace RV, Davey MP, Vasta V, Beavo JA, and Carr DW. 2004. A-kinase anchoring proteins interact with phosphodiesterases in T lymphocyte cell lines. J Immunol 173:4806-4814.
Bach ME, Barad M, Son H, Zhuo M, Lu YF, Shih R, Mansuy I, Hawkins RD, and Kandel ER. 1999. Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc Natl Acad Sci U S A 96:5280-5285.
Baecker PA, Obernolte R, Bach C, Yee C, and Shelton ER. 1994. Isolation of a cDNA encoding a human rolipram-sensitive cyclic AMP phosphodiesterase (PDE IVD). Gene 138:253-256.
Bibliografía
phosphodiesterase-4 enzymes. Curr Opin Cell Biol 17:129-134.
Baillie GS, Huston E, Scotland G, Hodgkin M, Gall I, Peden AH, MacKenzie C, Houslay ES, Currie R, Pettitt TR, Walmsley AR, Wakelam MJ, Warwicker J, and Houslay MD. 2002. TAPAS-1, a novel microdomain within the unique N-terminal region of the PDE4A1 cAMP-specific phosphodiesterase that allows rapid, Ca2+-triggered membrane association with selectivity for interaction with phosphatidic acid. J Biol Chem 277:28298-28309.
Baillie GS, MacKenzie SJ, McPhee I, and Houslay MD. 2000. Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br J Pharmacol 131:811-819.
Baillie GS, Scott JD, and Houslay MD. 2005. Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Lett 579:3264-3270.
Bajetto A, Bonavia R, Barbero S, Florio T, and Schettini G. 2001. Chemokines and their receptors in the central nervous system. Front Neuroendocrinol 22:147-184.
Bajetto A, Bonavia R, Barbero S, and Schettini G. 2002. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem 82:1311-1329.
Bal-Price A and Brown GC. 2001. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci 21:6480-6491. Ballerini P, Di Iorio P, Ciccarelli R, Nargi E,
D'Alimonte I, Traversa U, Rathbone MP, and Caciagli F. 2002. Glial cells express multiple ATP binding cassette proteins which are involved in ATP release. Neuroreport 13:1789-1792.
Baltrons MA, Pifarre P, Ferrer I, Carot JM, and Garcia A. 2004. Reduced expression of NO-sensitive guanylyl cyclase in reactive astrocytes of Alzheimer disease, Creutzfeldt-Jakob disease, and multiple sclerosis brains. Neurobiol Dis 17:462-472.
Barad M, Bourtchouladze R, Winder DG, Golan H, and Kandel E. 1998. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc Natl Acad Sci U S A 95:15020-15025.
Baranano DE, Ferris CD, and Snyder SH. 2001. Atypical neural messengers. Trends Neurosci 24:99-106.
Barnes AP, Livera G, Huang P, Sun C, O'Neal WK, Conti M, Stutts MJ, and Milgram SL. 2005. Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. J Biol Chem 280:7997-8003.
Barnes MJ, Cooper N, Davenport RJ, Dyke HJ, Galleway FP, Galvin FC, Gowers L, Haughan AF, Lowe C, Meissner JW, Montana JG,
Morgan T, Picken CL, and Watson RJ. 2001. Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors. Bioorg Med Chem Lett 11:1081-1083.
Baroja ML, Cieslinski LB, Torphy TJ, Wange RL, and Madrenas J. 1999. Specific CD3 epsilon association of a phosphodiesterase 4B isoform determines its selective tyrosine phosphorylation after CD3 ligation. J Immunol 162:2016-2023.
Basu A, Krady JK, and Levison SW. 2004. Interleukin-1: a master regulator of neuroinflammation. J Neurosci Res 78:151-156.
Baumer W, Hoppmann J, Rundfeldt C, and Kietzmann M. 2007. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets 6:17-26.
Bazan NG, Colangelo V, and Lukiw WJ. 2002. Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins Other Lipid Mediat 68-69:197-210.
Beard MB, O'Connell JC, Bolger GB, and Houslay MD. 1999. The unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains. FEBS Lett 460:173-177.
Beard MB, Olsen AE, Jones RE, Erdogan S, Houslay MD, and Bolger GB. 2000. UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions. J Biol Chem 275:10349-10358.
Beavo JA. 1995a. cGMP inhibition of heart phosphodiesterase: is it clinically relevant? [editorial; comment]. J Clin Invest 95:445.
Beavo JA. 1995b. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75:725-748. Beavo JA and Brunton LL. 2002. Cyclic nucleotide
research -- still expanding after half a century. Nat Rev Mol Cell Biol 3:710-718.
Beavo JA, Conti M, and Heaslip RJ. 1994. Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol 46:399-405.
Beavo JA, Hardman JG, and Sutherland EW. 1971. Stimulation of adenosine monophosphate hydrolysis by guanosine 3',5'-monophosphate. J Biol Chem 246:3841-3846. Beavo JA and Reifsnyder DH. 1990. Primary
sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 11:150-155.
Behn D and Potter MJ. 2001. Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the gamma-subunit of phosphodiesterase. Invest Ophthalmol Vis Sci 42:523-527.
Bibliografía
175
Berrendero F, Sanchez A, Cabranes A, Puerta C, Ramos JA, Garcia-Merino A, and Fernandez-Ruiz J. 2001. Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 41:195-202.
BERTHET J, RALL TW, and Sutherland EW. 1957. The relationship of epinephrine and glucagon to liver phosphorylase. IV. Effect of epinephrine and glucagon on the reactivation of phosphorylase in liver homogenates. J Biol Chem 224:463-475.
Bertolino A, Crippa D, di Dio S, Fichte K, Musmeci G, Porro V, Rapisarda V, Sastre, and Schratzer M. 1988. Rolipram versus imipramine in inpatients with major, "minor" or atypical depressive disorder: a double-blind double-dummy study aimed at testing a novel therapeutic approach. Int Clin Psychopharmacol 3:245-253.
Biber K, Sauter A, Brouwer N, Copray SC, and Boddeke HW. 2001. Ischemia-induced neuronal expression of the microglia attracting chemokine Secondary Lymphoid-tissue Chemokine (SLC). Glia 34:121-133.
Bielekova B, Lincoln A, McFarland H, and Martin R. 2000. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1- mediated autoimmune diseases. J Immunol 164:1117-1124.
Bigazzi PE. 1995. Animal models of multiple sclerosis. Clin Immunol Immunopathol 77:3. Blease K, Burke-Gaffney A, and Hellewell PG.
1998. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Br J Pharmacol 124:229-237.
Bliss TV and Gardner-Medwin AR. 1973. Long-lasting potentiation of synaptic transmission in the dentate area of the unanaestetized rabbit following stimulation of the perforant path. J Physiol 232:357-374.
Bliss TV and Lomo T. 1973. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol 232:331-356.
Blokland A, Schreiber R, and Prickaerts J. 2006. Improving memory: a role for phosphodiesterases. Curr Pharm Des 12:2511-2523.
Bloom TJ and Beavo JA. 1996. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc Natl Acad Sci U S A 93:14188-14192.
Blumer KJ and Johnson GL. 1994. Diversity in function and regulation of MAP kinase pathways. Trends Biochem Sci 19:236-240. Blusztajn JK and Berse B. 2000. The cholinergic
neuronal phenotype in Alzheimer's disease. Metab Brain Dis 15:45-64.
Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Sastre, Schratzer M, Troisfontaines B, von Frenckell
R, and Wachtel H. 1988. Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur Arch Psychiatry Neurol Sci 238:2-6.
Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de Vente J, Prickaerts J, Blokland A, and Koenig G. 2004. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 47:1081-1092.
Boguski MS and McCormick F. 1993. Proteins regulating Ras and its relatives. Nature 366:643-654.
Bolger G, Michaeli T, Martins T, St.John T, Steiner B, Rodgers L, Riggs M, Wigler M, and Ferguson K. 1993. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol 13:6558-6571.
Bolger GB, Erdogan S, Jones RE, Loughney K, Scotland G, Hoffmann R, Wilkinson I, Farrell C, and Houslay MD. 1997. Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem J 328 ( Pt 2):539-548.
Bolger GB, McCahill A, Huston E, Cheung YF, McSorley T, Baillie GS, and Houslay MD. 2003. The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins. J Biol Chem 278:49230-49238. Bolger GB, Rodgers L, and Riggs M. 1994.
Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases. Gene 149:237-244.
Bonkale WL, Cowburn RF, Ohm TG, Bogdanovic N, and Fastbom J. 1999. A quantitative autoradiographic study of [3H]cAMP binding to cytosolic and particulate protein kinase A in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits. Brain Res 818:383-396.
Bonkale WL, Winblad B, Ravid R, and Cowburn RF. 1995. Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease. Neurosci Lett 187:5-8.
Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, and Gingell C. 1996. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8:47-52.
Borinson H.L. and Wang SC. 1953. Physiology and pharmacology of vomiting. Pharmacol Rev 5:193-230.
Bibliografía
and gene control: the cAMP pathway. Crit Rev Oncog 3:321-338.
Borst P and Elferink RO. 2002. Mammalian ABC transporters in health and disease. Annual Review of Biochemistry 71:537-592.
Bouron A and Reuter H. 1999. The D1 dopamine receptor agonist SKF-38393 stimulates the release of glutamate in the hippocampus. Neuroscience 94:1063-1070.
Braak H and Braak E. 1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82:239-259.
Braak H and Braak E. 1997. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18:351-357. Braak H, Braak E, Bohl J, and Bratzke H. 1998.
Evolution of Alzheimer's disease related cortical lesions. J Neural Transm Suppl 54:97-106.
Bradley J, Zhang YN, Bakin R, Lester HA, Ronnett GV, and Zinn K. 1997. Functional expression of the heteromeric ''olfactory'' cyclic nucleotide-gated channel in the hippocampus: A potential effector of synaptic plasticity in brain neurons. Journal of Neuroscience 17:1993-2005. Brandon EP, Idzerda RL, and McKnight GS. 1997.
PKA isoforms, neural pathways, and behaviour: making the connection. Curr Opin Neurobiol 7:397-403.
Braun T and Dods RF. 1975. Development of A Mn2+-Sensitive, Soluble Adenylate Cyclase in Rat Testis. Proceedings of the National Academy of Sciences of the United States of America 72:1097-1101.
Breder CD, Hazuka C, Ghayur T, Klug C, Huginin M, Yasuda K, Teng M, and Saper CB. 1994. Regional induction of tumor necrosis factor alpha expression in the mouse brain after systemic lipopolysaccharide administration. Proc Natl Acad Sci U S A 91:11393-11397. Bredt DS and Snyder SH. 1989. Nitric oxide
mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci U S A 86:9030-9033.
Brenner S, Prosch S, Schenke-Layland K, Riese U, Gausmann U, and Platzer C. 2003. cAMP-induced Interleukin-10 promoter activation depends on CCAAT/enhancer-binding protein expression and monocytic differentiation. J Biol Chem 278:5597-5604.
Broadwell RD and Salcman M. 1981. Expanding the definition of the blood-brain barrier to protein. Proc Natl Acad Sci U S A 78:7820-7824.
Brown TH, Chapman PF, Kairiss EW, and Keenan CL. 1988. Long-term synaptic potentiation. Science 242:724-728.
Brown TH and Zador AM. 1990. Hippocampus. In Gordon M.Shepherd, editor. The Synaptic Organization of the Brain. New York: Oxford University Press. p 346-388.
Burgunder JM and Cheung PT. 1994. Expression of Soluble Guanylyl Cyclase Gene in Adult-Rat Brain. European Journal of Neuroscience 6:211-217.
Burns F, Zhao AZ, and Beavo JA. 1996. Cyclic nucleotide phosphodiesterases: gene complexity, regulation by phosphorylation, and physiological implications. Adv Pharmacol 36:29-48.
Butcher RW and Sutherland EW. 1962. Adenosine 3',5'-Phosphate in Biological Materials. J Biol Chem 237:1244-1250.
Byers D, Davis RL, and Kiger JAJ. 1981. Defect in cyclic AMP phosphodiesterase due to the dunce mutation of learning in Drosophila melanogaster. Nature 289:79-81.
Cali JJ, Parekh RS, and Krupinski J. 1996. Splice variants of type VIII adenylyl cyclase. Differences in glycosylation and regulation by Ca2+/calmodulin. J Biol Chem 271:1089-1095. Campbell IL. 2005. Cytokine-mediated
inflammation, tumorigenesis, and disease-associated JAK/STAT/SOCS signaling circuits in the CNS. Brain Res Brain Res Rev 48:166-177.
Campbell IL and Powell HC. 1996. Role of Cytokines in Demyelinating Disease Studied in Transgenic Mice. Methods 10:462-477.
Cannella B, Cross AH, and Raine CS. 1991. Adhesion-related molecules in the central nervous system. Upregulation correlates with inflammatory cell influx during relapsing experimental autoimmune encephalomyelitis. Lab Invest 65:23-31.
Cano E and Mahadevan LC. 1995. Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 20:117-122.
Cao C, Matsumura K, Yamagata K, and Watanabe Y. 1997. Involvement of cyclooxygenase-2 in LPS-induced fever and regulation of its mRNA by LPS in the rat brain. Am J Physiol 272:R1712-R1725.
Card GL, Blasdel L, England BP, Zhang C, Suzuki Y, Gillette S, Fong D, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, and Zhang KY. 2005. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol 23:201-207.
Carpenter DO, Briggs DB, Knox AP, and Strominger N. 1988. Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides. J Neurophysiol 59:358-369.
Carson MJ. 2002. Microglia as liaisons between the immune and central nervous systems: functional implications for multiple sclerosis. Glia 40:218-231.
Carson MJ, Reilly CR, Sutcliffe JG, and Lo D. 1998. Mature microglia resemble immature antigen-presenting cells. Glia 22:72-85.
Castro A, Abasolo MI, Gil C, Segarra V, and Martínez A. 2001. CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-alpha]thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors. Eur J Med Chem 36:333-338.
Bibliografía
177
their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med Res Rev 25:229-244.
Cellerino A, Bahr M, and Isenmann S. 2000. Apoptosis in the developing visual system. Cell and Tissue Research 301:53-69.
Chang BY, Conroy KB, Machleder EM, and Cartwright CA. 1998. RACK1, a receptor for activated C kinase and a homolog of the beta subunit of G proteins, inhibits activity of src tyrosine kinases and growth of NIH 3T3 cells. Mol Cell Biol 18:3245-3256.
Chang BY, Harte RA, and Cartwright CA. 2002. RACK1: a novel substrate for the Src protein-tyrosine kinase. Oncogene 21:7619-7629. Charbonneau H, Prusti RK, LeTrong H,
Sonnenburg WK, Mullaney PJ, Walsh KA, and Beavo JA. 1990. Identification of a noncatalytic cGMP-binding domain conserved in both the cGMP-stimulated and photoreceptor cyclic nucleotide phosphodiesterases. Proc Natl Acad Sci U S A 87:288-292.
Chelmickaschorr E, Kwasniewski MN, Thomas BE, and Arnason BGW. 1989. The Beta-Adrenergic Agonist Isoproterenol Suppresses Experimental Allergic Encephalomyelitis in Lewis Rats. Journal of Neuroimmunology 25:203-207.
Chen C and Regehr WG. 1997. The mechanism of cAMP-mediated enhancement at a cerebellar synapse. J Neurosci 17:8687-8694. Chen HW, Jiang WS, and Tzeng CR. 2001a. Nitric
oxide as a regulator in preimplantation embryo development and apoptosis. Fertility and Sterility 75:1163-1171.
Chen S, Dell EJ, Lin F, Sai J, and Hamm HE. 2004. RACK1 regulates specific functions of Gbetagamma. J Biol Chem 279:17861-17868. Chen S, Lin F, and Hamm HE. 2005. RACK1
binds to a signal transfer region of G betagamma and inhibits phospholipase C beta2 activation. J Biol Chem 280:33445-33452.
Chen Z, Nield HS, Sun H, Barbier A, and Patel TB. 1995. Expression of type V adenylyl cyclase is required for epidermal growth factor-mediated stimulation of cAMP accumulation. J Biol Chem 270:27525-27530.
Chen ZS, Lee K, and Kruh GD. 2001b. Transport of cyclic nucleotides and estradiol 17-beta-D-glueuronide by multidrug resistance protein 4 - Resistance to mercaptopurine and 6-thioguanine. Journal of Biological Chemistry 276:33747-33754.
Cheng JF and Grande JP. 2007. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: Novel therapeutic agents for progressive renal disease. Experimental Biology and Medicine 232:38-51.
Cherfils J and Chardin P. 1999. GEFs: structural basis for their activation of small GTP-binding proteins. Trends Biochem Sci 24:306-311. Cherry JA and Davis RL. 1999. Cyclic AMP
phosphodiesterases are localized in regions of the mouse brain associated with
reinforcement, movement, and affect. J Comp Neurol 407:287-301.
Chiang CS, Powell HC, Gold LH, Samimi A, and Campbell IL. 1996. Macrophage/microglial-mediated primary demyelination and motor disease induced by the central nervous system production of interleukin-3 in transgenic mice. J Clin Invest 97:1512-1524.
Choi YH, Ekholm D, Krall J, Ahmad F, Degerman E, Manganiello VC, and Movsesian MA. 2001. Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes. Biochem J 353:41-50.
Ciani E, Guidi S, Bartesaghi R, and Contestabile A. 2002. Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: implication for a survival role of nitric oxide. J Neurochem 82:1282-1289.
Cirillo MA and Seidman LJ. 2003. Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms. Neuropsychol Rev 13:43-77.
Coimbra R, Melbostad H, Loomis W, Tobar M, and Hoyt DB. 2005a. Phosphodiesterase inhibition decreases nuclear factor-kappaB activation and shifts the cytokine response toward anti-inflammatory activity in acute endotoxemia. J Trauma 59:575-582.
Coimbra R, Porcides RD, Melbostad H, Loomis W, Tobar M, Hoyt DB, and Wolf P. 2005b. Nonspecific phosphodiesterase inhibition attenuates liver injury in acute endotoxemia. Surg Infect (Larchmt ) 6:73-85.
Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Jacobsen JS, and Marquis KL. 2005. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 25:8898-8902.
Consilvio C, Vincent AM, and Feldman EL. 2004. Neuroinflammation, COX-2, and ALS--a dual role? Exp Neurol 187:1-10.
Conti M. 2000. Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. Mol Endocrinol 14:1317-1327.
Conti M and Jin SL. 1999. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 63:1-38.
Conti M, Nemoz G, Sette C, and Vicini E. 1995. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr Rev 16:370-389.
Conti M, Richter W, Mehats C, Livera G, Park JY, and Jin C. 2003. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493-5496.
Bibliografía
requires methylated, prenylated C-termini of the catalytic subunits. Biochemistry 39:13516-13523.
Cook TA, Ghomashchi F, Gelb MH, Florio SK, and Beavo JA. 2001. The delta subunit of type 6 phosphodiesterase reduces light-induced cGMP hydrolysis in rod outer segments. J Biol Chem 276:5248-5255.
Cooper DM, Mons N, and Karpen JW. 1995. Adenylyl cyclases and the interaction between calcium and cAMP signalling. Nature 374:421-424.
Coquil JF, Franks DJ, Wells JN, Dupuis M, and Hamet P. 1980. Characteristics of a new binding protein distinct from the kinase for guanosine 3':5'-monophosphate in rat platelets. Biochim Biophys Acta 631:148-165. Corbin JD. 2004. Mechanisms of action of PDE5
inhibition in erectile dysfunction. Int J Impot Res 16 Suppl 1:S4-S7.
Corbin JD and Francis SH. 1999. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 274:13729-13732.
Corbin JD, Ogreid D, Miller JP, Suva RH, Jastorff B, and Doskeland SO. 1986. Studies of Cgmp Analog Specificity and Function of the 2 Intrasubunit Binding-Sites of Cgmp-Dependent Protein-Kinase. Journal of Biological Chemistry 261:1208-1214.
Corbin JD, Thomas MK, Wolfe L, Shabb JB, Woodford TA, and Francis SH. 1990. New Insights Into Cgmp Action. Advances in Second Messenger and Phosphoprotein Research 24:411-418.
Corbin JD, Turko IV, Beasley A, and Francis SH. 2000. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 267:2760-2767. Correale J and Villa A. 2004. The neuroprotective
role of inflammation in nervous system injuries. J Neurol 251:1304-1316.
Cortés R, Mengod G, Celada P, and Artigas F. 1993. p-chlorophenylalanine increases tryptophan-5-hydroxylase mRNA levels in the rat dorsal raphe: a time course study using in situ hybridization. J Neurochem 60:761-764. Coskran TM, Morton D, Menniti FS, Adamowicz
WO, Kleiman RJ, Ryan AM, Strick CA, Schmidt CJ, and Stephenson DT. 2006. Immunohistochemical Localization of Phosphodiesterase 10A (PDE10A) in Multiple Mammalian Species. J Histochem Cytochem. Cowburn RF, Fowler CJ, and O'Neill C. 1996.
Neurotransmitters, signal transduction and second-messengers in Alzheimer's disease. Acta Neurol Scand Suppl 165:25-32.
Crespo P, Xu N, Simonds WF, and Gutkind JS. 1994. Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits. Nature 369:418-420.
Cserr HF and Knopf PM. 1992. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today 13:507-512.
Cummings JL, Donohue JA, and Brooks RL. 2000. The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease. Am J Geriatr Psychiatry 8:134-140.
Cummings JL, Vinters HV, Cole GM, and Khachaturian ZS. 1998. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 51:S2-17.
D'Amours MR, Granovsky AE, Artemyev NO, and Cote RH. 1999. Potency and mechanism of action of E4021, a type 5 phosphodiesterase isozyme-selective inhibitor, on the photoreceptor phosphodiesterase depend on the state of activation of the enzyme. Mol Pharmacol 55:508-514.
D'Andrea MR, Qiu Y, Haynes-Johnson D, Bhattacharjee S, Kraft P, and Lundeen S. 2005. Expression of PDE11A in normal and malignant human tissues. J Histochem Cytochem 53:895-903.
D'Sa C, Tolbert LM, Conti M, and Duman RS. 2002. Regulation of cAMP-specific phosphodiesterases type 4B and 4D (PDE4) splice variants by cAMP signaling in primary cortical neurons. J Neurochem 81:745-757. Dal Canto MC, Melvold RW, Kim BS, and Miller
SD. 1995. Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Microsc Res Tech 32:215-229.
Dauwalder B and Davis RL. 1995. Conditional rescue of the dunce learning/memory and female fertility defects with Drosophila or rat transgenes. J Neurosci 15:3490-3499.
Davis RL. 1996. Physiology and biochemistry of Drosophila learning mutants. Physiol Rev 76:299-317.
Davis RL, Cherry J, Dauwalder B, Han PL, and Skoulakis E. 1995. The cyclic AMP system and Drosophila learning. Mol Cell Biochem 149-150:271-278.
Davis RL, Takayasu H, Eberwine M, and Myres J. 1989. Cloning and characterization of mammalian homologs of the Drosophila dunce+ gene. Proc Natl Acad Sci U S A 86:3604-3608.
Davoren PR and Sutherland EW. 1963. Effect of L-Epinephrine and Other Agents on Synthesis and Release of Adenosine 3',5'-Phosphate by Whole Pigeon Erythrocytes. Journal of Biological Chemistry 238:3009-&.
de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, and Bos JL. 1998. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396:474-477.
de Vente J. 2004. cGMP: a second messenger for acetylcholine in the brain? Neurochem Int 45:799-812.
Bibliografía
179
and nitric oxide-receptive, cyclic GMP-producing structures in the rat brain. Neuroscience 87:207-241.
de Vente J, Markerink-Van Ittersum M, Axer H, and Steinbusch HW. 2001. Nitric-oxide-induced cGMP synthesis in cholinergic neurons in the rat brain. Exp Brain Res 136:480-491.
Defer N, Best-Belpomme M, and Hanoune J. 2000. Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. Am J Physiol Renal 279:F400-F416. Degerman E, Belfrage P, and Manganiello VC.
1997. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem 272:6823-6826.
Degerman E, Manganiello VC, Newman AH, Rice KC, and Belfrage P. 1988. Purification, properties and polyclonal antibodies for the particulate, low Km cAMP phosphodiesterase from bovine adipose tissue. Second Messengers Phosphoproteins 12:171-182. Del Maschio A, De Luigi A, Martin-Padura I,
Brockhaus M, Bartfai T, Fruscella P, Adorini L, Martino G, Furlan R, De Simoni MG, and Dejana E. 1999. Leukocyte recruitment in the cerebrospinal fluid of mice with experimental meningitis is inhibited by an antibody to junctional adhesion molecule (JAM). J Exp Med 190:1351-1356.
Denninger JW and Marletta MA. 1999. Guanylate cyclase and the .NO/cGMP signaling pathway. Biochim Biophys Acta 1411:334-350.
Dent G and Giembycz MA. 1996. Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma? Thorax 51:647-649.
Dietrich JB. 2002. The adhesion molecule ICAM-1 and its regulation in relation with the blood-brain barrier. J Neuroimmunol 128:58-68. Dinter H, Tse J, Halks-Miller M, Asarnow D,
Onuffer J, Faulds D, Mitrovic B, Kirsch G, Laurent H, Esperling P, Seidelmann D, Ottow E, Schneider H, Tuohy VK, Wachtel H, and Perez HD. 2000. The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. J Neuroimmunol 108:136-146.
Dodge KL, Khouangsathiene S, Kapiloff MS, Mouton R, Hill EV, Houslay MD, Langeberg LK, and Scott JD. 2001. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J 20:1921-1930.
Dodge-Kafka KL, Soughayer J, Pare GC, Carlisle Michel JJ, Langeberg LK, Kapiloff MS, and Scott JD. 2005. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 437:574-578.
Domek-Lopacinska K, Markerink-Van Ittersum M, Steinbusch HW,de Vente J. 2005a. Changes in expression of cGMP selective phosphodiesterases 2, 5 and 9 in the rat brain during aging. BMC Pharmacol 5 (Suppl 1), 15.
Ref Type: Journal (Full)
Domek-Lopacinska K, van de WM, Markerink-Van Ittersum M, Steinbusch HW, and de Vente J. 2005b. Nitric oxide-induced cGMP synthesis in the cholinergic system during the development and aging of the rat brain. Brain Res Dev Brain Res 158:72-81.
Dousa TP. 1999. Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int 55:29-62.
Dudai Y, Jan YN, Byers D, Quinn WG, and Benzer S. 1976. dunce, a mutant of Drosophila deficient in learning. Proc Natl Acad Sci U S A 73:1684-1688.
Dumaz N and Marais R. 2005. Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. FEBS J 272:3491-3504.
Dunkern TR and Hatzelmann A. 2005. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. Cell Signal 17:331-339.
Duplantier AJ, Biggers MS, Chambers RJ, Cheng JB, Cooper K, Damon DB, Eggler JF, Kraus KG, Marfat A, Masamune H, Pillar JS, Shirley JT, Umland JP, and Watson JW. 1996. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J Med Chem 39:120-125.
Duzic E and Lanier SM. 1992. Factors Determining the Specificity of Signal Transduction by Guanine Nucleotide-Binding Protein-Coupled Receptors .3. Coupling of Alpha-2-Adrenergic Receptor Subtypes in A Cell Type-Specific Manner. Journal of Biological Chemistry 267:24045-24052.
Dyke HJ and Montana JG. 2002. Update on the therapeutic potential of PDE4 inhibitors. Exp Opin Invest Drugs 11:1-13.
Eason MG and Liggett SB. 1995. Identification of A G(S) Coupling Domain in the Amino-Terminus of the 3Rd Intracellular Loop of the Alpha(2A)-Adrenergic Receptor - Evidence for Distinct Structural Determinants That Confer G(S) Versus G(I) Coupling. Journal of Biological Chemistry 270:24753-24760.
Eigler A, Siegmund B, Emmerich U, Baumann KH, Hartmann G, and Endres S. 1998. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol 63:101-107.
Bibliografía
El Husseini AED, Williams J, Reiner PB, Pelech S, and Vincent SR. 1999. Localization of the cGMP-dependent protein kinases in relation to nitric oxide synthase in the brain. Journal of Chemical Neuroanatomy 17:45-55.
Elmquist JK, Breder CD, Sherin JE, Scammell TE, Hickey WF, Dewitt D, and Saper CB. 1997. Intravenous lipopolysaccharide induces cyclooxygenase 2-like immunoreactivity in rat brain perivascular microglia and meningeal macrophages. J Comp Neurol 381:119-129. Elmquist JK, Scammell TE, Jacobson CD, and
Saper CB. 1996. Distribution of Fos-like immunoreactivity in the rat brain following intravenous lipopolysaccharide administration. J Comp Neurol 371:85-103.
Elson G, Dunn-Siegrist I, Daubeuf B, and Pugin J. 2007. Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria. Blood 109:1574-1583.
Endo H, Sasaki K, Tonosaki A, and Kayama T. 1998. Three-dimensional and ultrastructural ICAM-1 distribution in the choroid plexus, arachnoid membrane and dural sinus of inflammatory rats induced by LPS injection in the lateral ventricles. Brain Res 793:297-301. Engelhardt B, Wolburg-Buchholz K, and Wolburg
H. 2001. Involvement of the choroid plexus in central nervous system inflammation. Microsc Res Tech 52:112-129.
Engels P, Abdel'Al S, Hulley P, and Lubbert H. 1995a. Brain distribution of four rat homologues of the Drosophila dunce cAMP phosphodiesterase. J Neurosci Res 41:169-178.
Engels P, Fichtel K, and Lubbert H. 1994. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett 350:291-295.
Engels P, Sullivan M, Muller T, and Lubbert H. 1995b. Molecular cloning and functional expression in yeast of a human cAMP- specific phosphodiesterase subtype (PDE IV-C). FEBS Lett 358:305-310.
Essayan DM. 1999. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem Pharmacol 57:965-973.
Estevez AG, Spear N, Thompson JA, Cornwell TL, Radi R, Barbeito L, and Beckman JS. 1998. Nitric oxide-dependent production of cGMP supports the survival of rat embryonic motor neurons cultured with brain-derived neurotrophic factor. J Neurosci 18:3708-3714. Fallis RJ, Raine CS, and McFarlin DE. 1989.
Chronic relapsing experimental allergic encephalomyelitis in SJL mice following the adoptive transfer of an epitope-specific T cell line. J Neuroimmunol 22:93-105.
Farber DB and Tsang SH. 2003. Stationary night blindness or progressive retinal degeneration in mice carrying different alleles of PDE gamma. Front Biosci 8:s666-s675.
Farooqui AA and Horrocks LA. 2004. Brain phospholipases A2: a perspective on the
history. Prostaglandins Leukot Essent Fatty Acids 71:161-169.
Favot L, Keravis T, and Lugnier C. 2004. Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. Thromb Haemost 92:634-645.
Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA, and Phillips SC. 2000. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci U S A 97:3702-3707. Fearns C, Kravchenko VV, Ulevitch RJ, and
Loskutoff DJ. 1995. Murine CD14 gene expression in vivo: extramyeloid synthesis and regulation by lipopolysaccharide. J Exp Med 181:857-866.
Federman AD, Conklin BR, Schrader KA, Reed RR, and Bourne HR. 1992. Hormonal stimulation of adenylyl cyclase through Gi-protein beta gamma subunits. Nature 356:159-161.
Fedoroff S, Zhai R, and Novak JP. 1997. Microglia and astroglia have a common progenitor cell. J Neurosci Res 50:477-486.
Fierz W, Endler B, Reske K, Wekerle H, and Fontana A. 1985. Astrocytes as antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J Immunol 134:3785-3793. Fischmeister R, Castro L, Abi-Gerges A, Rochais
F, and Vandecasteele G. 2005. Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. Comp Biochem Physiol A Mol Integr Physiol 142:136-143. Fischmeister R and Mery PF. 1996. [Regulation of
cardiac calcium current by cGMP/NO route]. C R Seances Soc Biol Fil 190:181-206.
Fisher DA, Smith JF, Pillar JS, St Denis SH, and Cheng JB. 1998a. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 246:570-577.
Fisher DA, Smith JF, Pillar JS, St Denis SH, and Cheng JB. 1998b. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 273:15559-15564.
Fitzpatrick JJ, Stier L, Eichorn A, Dlugacz YD, O'Connor LJ, Salinas TK, Smith T, and White MT. 2004. Hospitalized elders: changes in functional and mental status. Outcomes Manag 8:52-56.
Fleming YM, Frame MC, and Houslay MD. 2004. PDE4-regulated cAMP degradation controls the assembly of integrin-dependent actin adhesion structures and REF52 cell migration. J Cell Sci 117:2377-2388.
Bibliografía
181
encephalomyelitis: a quantitative MRI study. Brain 127:616-627.
Forstermann U, Boissel JP, and Kleinert H. 1998. Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J 12:773-790.
Foster DC, Wedel BJ, Robinson SW, and Garbers DL. 1999. Mechanisms of regulation and functions of guanylyl cyclases. Rev Physiol Biochem Pharmacol 135:1-39.
Francis SH, Bessay EP, Kotera J, Grimes KA, Liu L, Thompson WJ, and Corbin JD. 2002a. Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity. J Biol Chem 277:47581-47587.
Francis SH and Corbin JD. 1994. Structure and function of cyclic nucleotide-dependent protein kinases. Annu Rev Physiol 56:237-272. Francis SH, Lincoln TM, and Corbin JD. 1980.
Characterization of a novel cGMP binding protein from rat lung. J Biol Chem 255:620-626.
Francis SH, Noblett BD, Todd BW, Wells JN, and Corbin JD. 1988. Relaxation of Vascular and Tracheal Smooth-Muscle by Cyclic-Nucleotide Analogs That Preferentially Activate Purified Cgmp-Dependent Protein-Kinase. Molecular Pharmacology 34:506-517.
Francis SH, Turko IV, and Corbin JD. 2001. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1-52.
Francis SH, Turko IV, and Corbin JD. 2002b. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1-52.
Frazer A. 1997. Pharmacology of antidepressants. J Clin Psychopharmacol 17 Suppl 1:2S-18S. Fredriksson R, Lagerstrom MC, Lundin LG, and
Schioth HB. 2003. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63:1256-1272.
Frenette R, Blouin M, Brideau C, Chauret N, Ducharme Y, Friesen RW, Hamel P, Jones TR, Laliberte F, Li C, Masson P, McAuliffe M, and Girard Y. 2002. Substituted
4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study
directed toward the improvement of pharmacokinetic parameters. Bioorg Med Chem Lett 12:3009-3013.
Frey U, Huang YY, and Kandel ER. 1993. Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons. Science 260:1661-1664.
Friedman WJ, Larkfors L, Ayer-LeLievre C, Ebendal T, Olson L, and Persson H. 1990. Regulation of beta-nerve growth factor expression by inflammatory mediators in hippocampal cultures. J Neurosci Res 27:374-382.
Fritz RB and McFarlin DE. 1989. Encephalitogenic epitopes of myelin basic protein. Chem Immunol 46:101-125.
Fujino M, Funeshima N, Kitazawa Y, Kimura H, Amemiya H, Suzuki S, and Li XK. 2003. Amelioration of experimental autoimmune encephalomyelitis in lewis rats by FTY720 treatment. Journal of Pharmacology and Experimental Therapeutics 305:70-77.
Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, and Omori K. 1999a. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 274:18438-18445.
Fujishige K, Kotera J, and Omori K. 1999b.
Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A [In Process Citation]. Eur J Biochem 266:1118-1127. Fujishige K, Kotera J, Yuasa K, and Omori K.
2000. The human phosphodiesterase PDE10A gene genomic organization and evolutionary relatedness with other PDEs containing GAF domains. Eur J Biochem 267:5943-5951. Furchgott RF and Zawadzki JV. 1980. The
obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373-376.
Furuyama T, Inagaki S, and Takagi H. 1993a. Distribution of type II adenylyl cyclase mRNA in the rat brain. Mol Brain Res 19:165-170. Furuyama T, Inagaki S, and Takagi H. 1993b.
Localizations of Alpha-1-Subunit and Beta-1-Subunit of Soluble Guanylate-Cyclase in the Rat-Brain. Molecular Brain Research 20:335-344.
Gal A, Orth U, Baehr W, Schwinger E, and Rosenberg T. 1994. Heterozygous missense mutation in the rod cGMP phosphodiesterase beta-subunit gene in autosomal dominant stationary night blindness. Nat Genet 7:64-68. Galperin MY, Nikolskaya AN, and Koonin EV.
2001. Novel domains of the prokaryotic two-component signal transduction systems. FEMS Microbiol Lett 203:11-21.
Gamanuma M, Yuasa K, Sasaki T, Sakurai N, Kotera J, and Omori K. 2003. Comparison of enzymatic characterization and gene organization of cyclic nucleotide phosphodiesterase 8 family in humans. Cell Signal 15:565-574.
Gantner F, Gotz C, Gekeler V, Schudt C, Wendel A, and Hatzelmann A. 1998. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. Br J Pharmacol 123:1031-1038. Garcia-Jimenez A, Cowburn RF, Ohm TG,
Bibliografía
Gardner C, Robas N, Cawkill D, and Fidock M. 2000. Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun 272:186-192. Garthwaite J. 1991. Glutamate, nitric oxide and
cell-cell signalling in the nervous system. Trends Neurosci 14:60-67.
Garthwaite J. 1995. Neural nitric oxide signalling. Trends Neurosci 18:51-52.
Garthwaite J and Boulton CL. 1995. Nitric oxide signaling in the central nervous system. Annu Rev Physiol 57:683-706.
Garthwaite J, Garthwaite G, Palmer RM, and Moncada S. 1989. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol 172:413-416. Gehrmann J, Mies G, Bonnekoh P, Banati R,
Iijima T, Kreutzberg GW, and Hossmann KA. 1993. Microglial reaction in the rat cerebral cortex induced by cortical spreading depression. Brain Pathol 3:11-17.
Genain CP, Roberts T, Davis RL, Nguyen MH, Uccelli A, Faulds D, Li Y, Hedgpeth J, and Hauser SL. 1995. Prevention of autoimmune demyelination in non-human primates by a cAMP- specific phosphodiesterase inhibitor. Proc Natl Acad Sci U S A 92:3601-3605.
Gether U. 2000. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 21:90-113.
Ghersa P, Hooft vH, Whelan J, Cambet Y, Pescini R, and DeLamarter JF. 1994. Inhibition of E-selectin gene transcription through a cAMP-dependent protein kinase pathway. J Biol Chem 269:29129-29137.
Giembycz MA. 2000. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs 59:193-212.
Giembycz MA, Corrigan CJ, Seybold J, Newton R, and Barnes PJ. 1996. Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 118:1945-1958. Gilles-Gonzalez MA and Gonzalez G. 2004.
Signal transduction by heme-containing PAS-domain proteins. J Appl Physiol 96:774-783. Gillespie PG and Beavo JA. 1988.
Characterization of a bovine cone photoreceptor phosphodiesterase purified by cyclic GMP-sepharose chromatography. J Biol Chem 263:8133-8141.
Giordano D, De Stefano ME, Citro G, Modica A, and Giorgi M. 2001. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim Biophys Acta 1539:16-27.
Glabinski AR, Tuohy VK, and Ransohoff RM. 1998. Expression of chemokines RANTES, MIP-1alpha and GRO-alpha correlates with inflammation in acute experimental
autoimmune encephalomyelitis. Neuroimmunomodulation 5:166-171.
Glavas NA, Ostenson C, Schaefer JB, Vasta V, and Beavo JA. 2001. T cell activation
up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc Natl
Acad Sci U S A 98:6319-6324.
Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, and Klein WL. 2003. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 100:10417-10422. Goodwin JS and Ceuppens J. 1983. Regulation of
the Immune-Response by Prostaglandins. Journal of Clinical Immunology 3:295-315. Gordon EJ, Myers KJ, Dougherty JP, Rosen H,
and Ron Y. 1995. Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 62:153-160.
Gouault N, Martin-Chouly CA, Lugnier C, Cupif JF, Tonnelier A, Feger F, Lagente V, and David M. 2004. Solid-phase synthesis and evaluation of libraries of substituted 4,5-dihydropyridazinones as vasodilator agents. J Pharm Pharmacol 56:1029-1037.
Greenwood J, Wang Y, and Calder VL. 1995. Lymphocyte adhesion and transendothelial migration in the central nervous system: the role of LFA-1, ICAM-1, VLA-4 and VCAM-1. off. Immunology 86:408-415.
Grigoriadis N, Tselios T, Deraos S, Orologas A, Deraos G, Matsoukas J, Mavromatis L, and Milonas I. 2005. Animal models of central nervous system immune-mediated diseases: Therapeutic interventions with bioactive peptides and mimetics. Current Medicinal Chemistry 12:1513-1519.
Gross SS and Wolin MS. 1995. Nitric oxide: pathophysiological mechanisms. Annu Rev Physiol 57:737-769.
Gross-Langenhoff M, Hofbauer K, Weber J, Schultz A, and Schultz JE. 2006. cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. J Biol Chem 281:2841-2846.
Gudermann T, Kalkbrenner F, and Schultz G. 1996. Diversity and selectivity of receptor-G protein interaction. Annu Rev Pharmacol Toxicol 36:429-459.
Guipponi M, Scott HS, Kudoh J, Kawasaki K, Shibuya K, Shintani A, Asakawa S, Chen H, Lalioti MD, Rossier C, Minoshima S, Shimizu N, and Antonarakis SE. 1998. Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: alternative splicing of mRNA transcripts, genomic structure and sequence. Hum Genet 103:386-392.
Bibliografía
183
Response to Cgmp-Elevating and Camp-Elevating Vasodilators. Journal of Biological Chemistry 265:3088-3093.
Han P, Werber J, Surana M, Fleischer N, and Michaeli T. 1999. The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion. Journal of Biological Chemistry 274:22337-22344.
Han P, Zhu X, and Michaeli T. 1997. Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J Biol Chem 272:16152-16157.
Hanoune J and Defer N. 2001. Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 41:145-174.
Hanoune J, Pouille Y, Tzavara E, Shen T, Lipskaya L, Miyamoto N, Suzuki Y, and Defer N. 1997. Adenylyl cyclases: structure, regulation and function in an enzyme superfamily. Mol Cell Endocrinol 128:179-194. Hansen G, Jin S, Umetsu DT, and Conti M. 2000.
Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D [In Process Citation]. Proc Natl Acad Sci U S A 97:6751-6756.
Hardman JG and Sutherland EW. 1969. Guanyl cyclase, an enzyme catalyzing the formation of guanosine 3',5'-monophosphate from guanosine trihosphate. J Biol Chem 244:6363-6370.
Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafranca MN, Adhikari S, Thompson DA, Botti P, Bacon KB, and Feng L. 1998. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A 95:10896-10901. Harrison SA, Reifsnyder DH, Gallis B, Cadd GG,
and Beavo JA. 1986. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol Pharmacol 29:506-514.
Hayashi M, Matsushima K, Ohashi H, Tsunoda H, Murase S, Kawarada Y, and Tanaka T. 1998. Molecular cloning and characterization of human PDE8B, a novel thyroid- specific isozyme of 3',5'-cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun 250:751-756.
Hayashi M, Shimada Y, Nishimura Y, Hama T, and Tanaka T. 2002. Genomic organization, chromosomal localization, and alternative splicing of the human phosphodiesterase 8B gene. Biochem Biophys Res Commun 297:1253-1258.
Haynes L and Yau KW. 1985. Cyclic Gmp-Sensitive Conductance in Outer Segment Membrane of Catfish Cones. Nature 317:61-64.
Hebb AL, Robertson HA, and Denovan-Wright EM. 2004. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's
disease transgenic mice prior to the onset of motor symptoms. Neuroscience 123:967-981. Hendrix M. 2005. Selective inhibitors of cGMP
phosphodiesterases as procognitive agents. BMC Pharmacol 5 (Suppl. I) S5.
Hetman JM, Robas N, Baxendale R, Fidock M, Phillips SC, Soderling SH, and Beavo JA. 2000a. Cloning and characterization of two splice variants of human phosphodiesterase 11A. Proc Natl Acad Sci U S A 97:12891-12895.
Hetman JM, Soderling SH, Glavas NA, and Beavo JA. 2000b. Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. Proc Natl Acad Sci U S A 97:472-476.
Hickey WF. 1999. Leukocyte traffic in the central nervous system: the participants and their roles. Semin Immunol 11:125-137.
Hickey WF, Vass K, and Lassmann H. 1992. Bone marrow-derived elements in the central nervous system: an immunohistochemical and ultrastructural survey of rat chimeras. J Neuropathol Exp Neurol 51:246-256.
Hildebrandt JD. 1997. Role of subunit diversity in signaling by heterotrimeric G proteins. Biochem Pharmacol 54:325-339.
Hirrlinger J, Konig J, and Dringen R. 2002. Expression of mRNAs of multidrug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurones. Journal of Neurochemistry 82:716-719.
Hobbs AJ. 1997. Soluble guanylate cyclase: the forgotten sibling. Trends Pharmacol Sci 18:484-491.
Hoeper MM. 2005. Drug treatment of pulmonary arterial hypertension: current and future agents. Drugs 65:1337-1354.
Hoffmann R, Abdel'Al S, and Engels P. 1998a. Differential distribution of rat PDE-7 mRNA in embryonic and adult rat brain. Cell Biochem Biophys 28:103-113.
Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood SJ, and Houslay MD. 1999. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J 18:893-903.
Hoffmann R, Wilkinson IR, McCallum JF, Engels P, and Houslay MD. 1998b. cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. Biochem J 333 ( Pt 1):139-149.
Hong KW, Lee JH, Kim KY, Park SY, and Lee WS. 2006. Cilostazol: Therapeutic potential against focal cerebral ischemic damage. Current Pharmaceutical Design 12:565-573. Hopkins SJ. 2007. Central nervous system
recognition of peripheral inflammation: a neural, hormonal collaboration. Acta Biomed 78 Suppl 1:231-247.
Bibliografía
human type IVA (PDE-IVA) cyclic AMP phosphodiesterase and localization of the gene to the p13.2- q12 region of human chromosome 19 [corrected] [published erratum appears in Biochem J 1995 Dec 15;312(Pt 3):991]. Biochem J 308 ( Pt 2):683-691. Houslay MD. 1995. Compartmentalization of cyclic
AMP phosphodiesterases, signalling 'crosstalk', desensitization and the phosphorylation of Gi-2 add cell specific personalization to the control of the levels of the second messenger cyclic AMP. Adv Enzyme Regul 35:303-338.
Houslay MD. 1998. Adaptation in cyclic AMP signalling processes: a central role for cyclic AMP phosphodiesterases. Semin Cell Dev Biol 9:161-167.
Houslay MD. 2001. PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol 69:249-315.
Houslay MD and Adams DR. 2003. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1-18.
Houslay MD and Kolch W. 2000. Cell-type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signaling. Mol Pharmacol 58:659-668.
Houslay MD and Milligan G. 1997. Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem Sci 22:217-224. Houslay MD, Schafer P, and Zhang KY. 2005.
Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10:1503-1519.
Houslay MD, Sullivan M, and Bolger GB. 1998. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv Pharmacol 44:225-342.
Howard KM and Olson MS. 2000. The expression and localization of plasma platelet-activating factor acetylhydrolase in endotoxemic rats. J Biol Chem 275:19891-19896.
Hu H, McCaw EA, Hebb AL, Gomez GT, and Denovan-Wright EM. 2004. Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. Eur J Neurosci 20:3351-3363.
Huai Q, Colicelli J, and Ke H. 2003. The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry 42:13220-13226.
Huang Z, Ducharme Y, Macdonald D, and Robichaud A. 2001. The next generation of PDE4 inhibitors. Curr Opin Chem Biol 5:432-438.
Humpl T, Reyes JT, Holtby H, Stephens D, and Adatia I. 2005. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 111:3274-3280.
Huston E, Beard M, McCallum F, Pyne NJ, Vandenabeele P, Scotland G, and Houslay MD. 2000. The cAMP-specific phosphodiesterase PDE4A5 is cleaved downstream of its SH3 interaction domain by caspase-3. Consequences for altered intracellular distribution. J Biol Chem 275:28063-28074.
Huston E, Lumb S, Russell A, Catterall C, Ross AH, Steele MR, Bolger GB, Perry MJ, Owens RJ, and Houslay MD. 1997. Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3. Biochem J 328 ( Pt 2):549-558.
Huston E, Pooley L, Julien P, Scotland G, McPhee I, Sullivan M, Bolger G, and Houslay MD. 1996. The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram. J Biol Chem 271:31334-31344.
Ibrahim SM, Mix E, Bottcher T, Koczan D, Gold R, Rolfs A, and Thiesen HJ. 2001. Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain 124:1927-1938.
Ichimura M and Kase H. 1993. A new cyclic nucleotide phosphodiesterase isozyme expressed in the T- lymphocyte cell lines. Biochem Biophys Res Commun 193:985-990. Ignarro LJ, Buga GM, Wood KS, Byrns RE, and
Chaudhuri G. 1987a. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 84:9265-9269.
Ignarro LJ, Byrns RE, Buga GM, and Wood KS. 1987b. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 61:866-879.
Issazadeh S, Ljungdahl A, Hojeberg B, Mustafa M, and Olsson T. 1995a. Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor beta. J Neuroimmunol 61:205-212.
Issazadeh S, Mustafa M, Ljungdahl A, Hojeberg B, Dagerlind A, Elde R, and Olsson T. 1995b. Interferon gamma, interleukin 4 and transforming growth factor beta in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. J Neurosci Res 40:579-590. Ito M, Nishikawa M, Fujioka M, Miyahara M, Isaka
Bibliografía
185
Iwahashi Y, Furuyama T, Tano Y, Ishimoto I, Shimomura Y, and Inagaki S. 1996. Differential distribution of mRNA encoding cAMP-specific phosphodiesterase isoforms in the rat brain. Mol Brain Res 38:14-24.
Iyengar R. 1996. Gating by cyclic AMP: expanded role for an old signaling pathway. Science 271:461-463.
Jacobitz S, McLaughlin MM, Livi GP, Burman M, and Torphy TJ. 1996. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol Pharmacol 50:891-899.
Jacobitz S, Ryan MD, McLaughlin MM, Livi GP, DeWolf WEJ, and Torphy TJ. 1997. Role of conserved histidines in catalytic activity and inhibitor binding of human recombinant phosphodiesterase 4A. Mol Pharmacol 51:999-1006.
Janeway CA, Jr. and Medzhitov R. 2002. Innate immune recognition. Annu Rev Immunol 20:197-216.
Jarchau T, Hausler C, Markert T, Pohler D, Vandekerckhove J, Dejonge HR, Lohmann SM, and Walter U. 1994. Cloning, Expression, and In-Situ Localization of Rat Intestinal
Cgmp-Dependent Protein-Kinase-Ii. Proceedings of the National Academy of
Sciences of the United States of America 91:9426-9430.
Jedlitschky G, Burchell B, and Keppler D. 2000. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. Journal of Biological Chemistry 275:30069-30074.
Jee Y, Liu RL, Bai XF, Campagnolo DI, Shi FD, and Vollmer TL. 2006. Do T(h)2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis? International Immunology 18:537-544.
Jeffery P. 2005. Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD. Pulm Pharmacol Ther 18:9-17.
Jin SL and Conti M. 2002. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A 99:7628-7633.
Jin SL, Lan L, Zoudilova M, and Conti M. 2005a. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 175:1523-1531. Jin SL, Latour AM, and Conti M. 2005b.
Generation of PDE4 knockout mice by gene targeting. Methods Mol Biol 307:191-210. Jin SL, Richard FJ, Kuo WP, D'Ercole AJ, and
Conti M. 1999. Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D- deficient mice. Proc Natl Acad Sci U S A 96:11998-12003.
Jin SL, Swinnen JV, and Conti M. 1992. Characterization of the structure of a low Km, rolipram-sensitive cAMP phosphodiesterase. Mapping of the catalytic domain. J Biol Chem 267:18929-18939.
Jordan FL and Thomas WE. 1988. Brain macrophages: questions of origin and interrelationship. Brain Res 472:165-178. Jordan JD and Iyengar R. 1998. Modes of
interactions between signaling pathways. Biochem Pharmacol 55:1347-1352.
Juilfs DM, Fulle HJ, Zhao AZ, Houslay MD, Garbers DL, and Beavo JA. 1997. A subset of olfactory neurons that selectively express cGMP-stimulated phosphodiesterase (PDE2) and guanylyl cyclase-D define a unique olfactory signal transduction pathway. Proc Natl Acad Sci U S A 94:3388-3395.
Kajimura N, Yamazaki M, Morikawa K, Yamazaki A, and Mayanagi K. 2002. Three-dimensional structure of non-activated cGMP phosphodiesterase 6 and comparison of its image with those of activated forms. J Struct Biol 139:27-38.
Kakkar R, Raju RV, Rajput AH, and Sharma RK. 1996. Inhibition of bovine brain
calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by deprenyl. Life
Sci 59:L337-L341.
Kakkar R, Raju RV, and Sharma RK. 1999. Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1). Cell Mol Life Sci 55:1164-1186.
Kalyvas A and David S. 2004. Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron 41:323-335.
Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, and Czerwiec F. 2003. Cilostazol as a unique antithrombotic agent. Curr Pharm Des 9:2289-2302.
Kammer GM, Boehm CA, Rudolph SA, and Schultz LA. 1988. Mobility of the human T lymphocyte surface molecules CD3, CD4, and CD8: regulation by a cAMP-dependent pathway. Proc Natl Acad Sci U S A 85:792-796.
Kanda N and Watanabe S. 2001. Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells. Biochem Pharmacol 62:495-507.
Kandel ER and Schwartz JH. 1982. Molecular biology of learning: modulation of transmitter release. Science 218:433-443.
Karpus WJ and Ransohoff RM. 1998. Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. J Immunol 161:2667-2671.
Kasuya J, Goko H, and Fujita-Yamaguchi Y. 1995. Multiple transcripts for the human cardiac form of the cGMP-inhibited cAMP phosphodiesterase. J Biol Chem 270:14305-14312.
Katsuki H and Okuda S. 1995. Arachidonic acid as a neurotoxic and neurotrophic substance. Prog Neurobiol 46:607-636.
Bibliografía
Kawasaki H, Sprihtgett GM, Toki S, Canales JJ, Harlan P, Blumenstiel JP, Chen EJ, Bany IA, Mochizuki N, Ashbacher A, Matsuda M, Housman DE, and Graybiel AM. 1998a. A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia. Proceedings of the National Academy of Sciences of the United States of America 95:13278-13283.
Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE, and Graybiel AM. 1998b. A family of cAMP-binding proteins that directly activate Rap1. Science 282:2275-2279.
Kelly JJ, Barnes PJ, and Giembycz MA. 1996. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(- )-rolipram binding by selective inhibitors. Biochem J 318 ( Pt 2):425-436. Kenan Y, Murata T, Shakur Y, Degerman E, and
Manganiello VC. 2000. Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms. J Biol Chem 275:12331-12338.
Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, and Hohlfeld R. 2003. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 53:292-304. Khoury SJ, Hancock WW, and Weiner HL. 1992. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 176:1355-1364.
Kida S, Steart PV, Zhang ET, and Weller RO. 1993. Perivascular cells act as scavengers in the cerebral perivascular spaces and remain distinct from pericytes, microglia and macrophages. Acta Neuropathol (Berl) 85:646-652.
Kiemer AK, Hartung T, and Vollmar AM. 2000. cGMP-mediated inhibition of TNF-alpha production by the atrial natriuretic peptide in murine macrophages. J Immunol 165:175-181. Kiemer AK and Vollmar AM. 1998. Autocrine
regulation of inducible nitric-oxide synthase in macrophages by atrial natriuretic peptide. J Biol Chem 273:13444-13451.
Kihara Y, Ishii S, Kita Y, Toda A, Shimada A, and Shimizu T. 2005. Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor. Journal of Experimental Medicine 202:853-863.
Kim NN, Huang YH, Goldstein I, Bischoff E, and Trais AM. 2001. Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor. Life Sci 69:2249-2256.
Kim YM, Chung HT, Kim SS, Han JA, Yoo YM, Kim KM, Lee GH, Yun HY, Green A, Li J, Simmons RL, and Billiar TR. 1999. Nitric oxide protects PC12 cells from serum
deprivation-induced apoptosis by cGMP-dependent inhibition of caspase signaling. J Neurosci 19:6740-6747.
Kincaid RL, Balaban CD, and Billingsley ML. 1992. Regional and developmental expression of calmodulin-dependent cyclic nucleotide phosphodiesterase in rat brain. Adv Second Messenger Phosphoprotein Res 25:111-122. King CD and Mayer SE. 1974. Inhibition of Egress
of Adenosine-3',5'-Monophosphate from Pigeon Erythrocytes. Molecular Pharmacology 10:941-953.
Kingston PA, Zufall F, and Barnstable CJ. 1999. Widespread expression of olfactory cyclic nucleotide-gated channel genes in rat brain: Implications for neuronal signalling. Synapse 32:1-12.
Klussmann E, Maric K, Wiesner B, Beyermann M, and Rosenthal W. 1999. Protein kinase A anchoring proteins are required for vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. J Biol Chem 274:4934-4938. Kobayashi Y, Kawai K, Honda H, Tomida S, Niimi
N, Tamatani T, Miyasaka M, and Yoshikai Y. 1995. Antibodies against leukocyte function-associated antigen-1 and against intercellular adhesion molecule-1 together suppress the progression of experimental allergic encephalomyelitis. Cell Immunol 164:295-305. Kool M, deHaas M, Scheffer GL, Scheper RJ,
vanEijk MJT, Juijn JA, Baas F, and Borst P. 1997. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Research 57:3537-3547.
Kotera J, Fujishige K, Akatsuka H, Imai Y, Yanaka N, and Omori K. 1998. Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase. Journal of Biological Chemistry 273:26982-26990.
Kotera J, Fujishige K, Imai Y, Kawai E, Michibata H, Akatsuka H, Yanaka N, and Omori K. 1999a. Genomic origin and transcriptional regulation of two variants of cGMP-binding cGMP-specific phosphodiesterases. Eur J Biochem 262:866-873.
Kotera J, Fujishige K, and Omori K. 2000. Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues. J Histochem Cytochem 48:685-693.
Kotera J, Fujishige K, Yuasa K, and Omori K. 1999b. Characterization and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyzes cAMP and cGMP. Biochem Biophys Res Commun 261:551-557.
